Study guide

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow

Key Takeaways Explain This Topic AI

Maternal plasma volume expands by 45-50% while erythrocyte volume increases by only 20-30%, producing the physiological anaemia of pregnancy with a normal term haemoglobin nadir of 10.5-11.0 g/dL.

Progesterone directly stimulates the central respiratory center, driving a 45-50% increase in minute ventilation via tidal volume, lowering baseline arterial P a CO 2 P_a\text{CO}_2 P a ​ CO 2 ​ to 28-32 mmHg with compensatory renal bicarbonate reduction to 18-21 mEq/L.

Functional residual capacity decreases by 20% upright and 30-35% supine, while closing capacity remains unchanged; closing capacity exceeds FRC in the supine position, which together with a 20-40% increase in O 2 \text{O}_2 O 2 ​ consumption precipitates rapid hypoxaemic desaturation during induction.

Aortocaval compression by the gravid uterus begins at 20 weeks gestation, reducing venous return and cardiac output by up to 25-30% in the supine position; it is mitigated by a 15-degree left lateral tilt.

The uteroplacental vascular bed is maximally dilated and non-autoregulated; uterine blood flow depends entirely on perfusion pressure ( U P P = U A P − U V P U V R UPP = \frac{UAP - UVP}{UVR} U PP = U V R U A P − U V P ​ ) and is compromised by maternal hypotension, excessive uterine contractions, and high-dose alpha-1 adrenergic vasoconstrictors.

Last updated: October 2026

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow

Pregnancy elicits extensive anatomical, biochemical, and physiological transformations across virtually every organ system. These adaptations accommodate fetal development, satisfy the high metabolic requirements of the fetoplacental unit, and prepare the parturient for blood loss at delivery. For the anaesthetist, failure to account for these adaptations dramatically elevates the risks of failed tracheal intubation, fatal pulmonary aspiration, catastrophic aortocaval compression, and fetal hypoxaemia.

1. Maternal Cardiovascular Adaptations

Cardiovascular remodeling begins during the first trimester, primarily driven by hormonal surges (estrogen, progesterone, and local prostacyclins) and the development of the low-resistance uteroplacental circulation. [ Hormonal Surge: Progesterone, PGI2, NO ]

  • |
  • +----------------------+----------------------+
  • | |
  • [ Marked Vasodilation ] [ RAAS Activation ]
  • | |
  • SVR Decreases by 20-30% Plasma Volume Expands (+45-50%)
  • | Erythrocyte Mass Expands (+20-30%)
  • Mid-trimester BP Nadir |
  • | [ Physiological Anaemia ]
  • +----------------------+----------------------+
  • |
  • [ Cardiac Output Rises +40-50% ]
  • Early: Stroke Volume Increases (+30%)
  • Late: Heart Rate Increases (+15-20 bpm)
  • Intravascular Volume and Physiological Anaemia

Plasma Volume: Increases by 45% to 50% above non-pregnant levels, beginning as early as 6 to 8 weeks gestation and plateauing around 32 to 34 weeks. This expansion is mediated by progesterone- and estrogen-stimulated activation of the renin-angiotensin-aldosterone system (RAAS), leading to sodium and water retention.

Erythrocyte Mass: Erythropoietin production increases red blood cell (RBC) mass by 20% to 30% (up to 40% with iron supplementation).

Physiological Anaemia of Pregnancy: Because plasma volume expansion markedly outstrips erythrocyte proliferation, relative hemodilution occurs. Whole blood viscosity decreases by roughly 20%, reducing maternal cardiac work and optimizing capillary perfusion through the intervillous space. At term, the normal haemoglobin concentration ranges from 10.5 to 11.0 g/dL (haematocrit ~32% to 34%). True pathological anaemia is defined as haemoglobin < 11.0 g/dL < 11.0\text{ g/dL} < 11.0 g/dL in the first and third trimesters, or < 10.5 g/dL < 10.5\text{ g/dL} < 10.5 g/dL in the second trimester.

Cardiac Output and Ventricular Dynamics

Baseline Elevation: Cardiac output ( C O CO CO ) increases by 40% to 50% by the late second trimester (28-32 weeks). Early in gestation, this rise is driven primarily by an increase in stroke volume ( S V SV S V , +30%) secondary to volume expansion and increased myocardial contractility. Later in gestation, maternal heart rate ( H R HR H R ) increases by 15 to 20 bpm (+15% to 25%), sustaining cardiac output as stroke volume plateaus.

Labour and Delivery Surges: Each uterine contraction expels 300 to 500 mL of blood from the choriodecidual space into the maternal venous circulation (autotransfusion). This intermittently raises cardiac output by 40% to 80% above pre-labour values, accompanied by transient elevations in systolic and diastolic arterial pressures.

Immediate Postpartum Peak: Following placental delivery, relief of aortocaval compression combined with profound autotransfusion from the strongly contracted myometrium produces a massive surge in effective circulating volume. Cardiac output peaks at 60% to 80% above pre-labour baselines within the first 10 to 30 minutes postpartum. This period poses the highest risk of acute decompensation and hydrostatic pulmonary edema in parturients with fixed cardiac output states (e.g. mitral stenosis, aortic stenosis, or severe pulmonary hypertension).

Vascular Resistance and Systemic Blood Pressure

Systemic Vascular Resistance (SVR): Decreases by 20% to 30% . The low-resistance uteroplacental vascular shunt, coupled with increased circulating levels of vasodilatory mediators—including prostacyclin ( P G I 2 PGI_2 PG I 2 ​ ), nitric oxide ( N O NO NO ), and relaxin—promotes widespread vascular relaxation.

Blood Pressure Trends: Diastolic and mean arterial pressures drop progressively to reach a nadir at 24 to 28 weeks gestation (typically 10-15 mmHg below baseline) before gradually returning toward pre-pregnancy values near term. Systolic blood pressure is minimally altered.

Pulmonary Vascular Resistance (PVR): Decreases by 30% to 35% , maintaining low pulmonary arterial pressures despite the expanded circulating volume.

Aortocaval Compression and Supine Hypotensive Syndrome

From approximately 20 weeks gestation onwards, the enlarging gravid uterus compresses both the inferior vena cava (IVC) and the distal abdominal aorta when the patient is in the supine position.

Vena Caval Compression: Restricts venous return from the lower limbs and pelvis, precipitating an abrupt fall in right atrial pressure, stroke volume, and cardiac output by up to 25% to 30% . In approximately 10% to 15% of parturients, collateral paravertebral and azygos venous flow is insufficient to sustain venous return, resulting in supine hypotensive syndrome (pallor, dizziness, diaphoresis, tachycardia followed by vagal bradycardia, and arterial collapse).

Aortic Compression: Directly impedes arterial outflow distal to the L4 bifurcation, reducing perfusion pressure to the hypogastric and uterine arteries even in the absence of measurable brachial arterial hypotension.

Clinical Mitigation: A mandatory 15-degree left lateral tilt or pelvic wedge displacement must be applied during all procedures, transport, and operative deliveries from 20 weeks gestation to relieve caval obstruction.

  • Cardiovascular Parameter Change at Term vs Non-Pregnant Anaesthetic Significance
  • Total Blood Volume Increases +40% to 50% Protects against normal peripartum blood loss (500-1000 mL)
  • Plasma Volume Increases +45% to 50% Causes physiological anaemia; decreases blood viscosity
  • Erythrocyte Mass Increases +20% to 30% Enhanced oxygen-carrying capacity
  • Cardiac Output Increases +40% to 50% Hyperdynamic state; peaks immediately postpartum
  • Stroke Volume Increases +30% (early peak) Contributes to early cardiac output surge
  • Heart Rate Increases +15 to 20 bpm Baseline maternal resting tachycardia
  • Systemic Vascular Resistance Decreases -20% to 30% Promotes baseline peripheral vasodilation
  • Pulmonary Vascular Resistance Decreases -30% to 35% Prevents pulmonary arterial hypertension
  • 2. Respiratory Adaptations and Airway Implications
  • Ventilatory Drive and Acid-Base Physiology

Progesterone Effect: High levels of circulating progesterone act as a potent direct stimulant of the medullary respiratory center and increase its sensitivity to arterial carbon dioxide. Minute ventilation increases by 45% to 50% above pre-pregnancy baselines.

Ventilatory Mechanics: This elevation is achieved primarily through a 40% to 50% increase in tidal volume ( V T V_T V T ​ ) ; the respiratory rate ( R R RR RR ) remains largely unchanged or increases by only 1 to 2 breaths per minute.

Arterial Blood Gas Equilibrium: Elevated alveolar ventilation leads to an increased elimination of carbon dioxide, lowering the resting arterial partial pressure of carbon dioxide ( P a CO 2 P_a\text{CO}_2 P a ​ CO 2 ​ ) to 28 to 32 mmHg (3.7 to 4.3 kPa), down from the non-pregnant baseline of 40 mmHg (5.3 kPa). Concurrently, maternal arterial P a O 2 P_a\text{O}_2 P a ​ O 2 ​ rises to 100 to 105 mmHg (13.3 to 14.0 kPa) on room air during the first trimester, settling around 100 mmHg at term.

Renal Compensation: To preserve physiological pH in the presence of chronic respiratory alkalosis, the maternal kidneys compensate over several weeks by increasing bicarbonate excretion. Plasma bicarbonate concentrations drop to 18 to 21 mEq/L (from 24 mEq/L), establishing a compensated chronic respiratory alkalosis with a normal maternal arterial pH of 7.40 to 7.44 . This lower maternal P a CO 2 P_a\text{CO}_2 P a ​ CO 2 ​ creates a steep transplacental concentration gradient ( P CO 2 P\text{CO}_2 P CO 2 ​ differential of 10-15 mmHg) that facilitates diffusion of fetal metabolic CO 2 \text{CO}_2 CO 2 ​ into the maternal circulation. [ Elevated Progesterone ] --> Drives Medullary Respiratory Center

  • |
  • Tidal Volume Rises (+40-50%)
  • Minute Ventilation Rises (+45-50%)
  • |
  • Alveolar Hyperventilation
  • |
  • PaCO2 Falls to 28-32 mmHg (3.7-4.3 kPa)
  • |
  • Compensatory Renal Bicarbonate Excretion
  • |
  • Serum HCO3- Decreases to 18-21 mEq/L
  • |
  • Net Result: Compensated Chronic Respiratory Alkalosis (pH 7.40-7.44)
  • Lung Volumes and Atelectasis Mechanics

Diaphragmatic Displacement: The cranial expansion of the gravid uterus elevates the resting diaphragm by up to 4 cm , while relaxin-induced laxity of the costal cartilages widens the subcostal angle and increases the transverse thoracic diameter by ~2 cm. Total lung capacity (TLC) declines minimally (by 0% to 5%).

Functional Residual Capacity (FRC): The upward diaphragmatic shift compresses the pulmonary bases, decreasing FRC by 20% in the upright position and by 30% to 35% in the supine position at term. This reduction is driven almost entirely by a 40% to 50% decline in Expiratory Reserve Volume (ERV) , alongside a slight 10% to 15% reduction in Residual Volume (RV) .

Closing Capacity Relationship: Closing volume and closing capacity (CC) remain unchanged throughout normal pregnancy. However, because FRC declines below CC in the supine position—and in up to 30% of standing parturients near term—small airway closure occurs within dependent lung zones during ordinary tidal ventilation. This causes progressive micro-atelectasis, intrapulmonary right-to-left shunting, and ventilation-perfusion ( V / Q V/Q V / Q ) mismatch.

Rapid Desaturation Mechanism: Maternal basal oxygen consumption ( O 2 \text{O}_2 O 2 ​ consumption) increases by 20% to 40% at term (and up to 60% to 100% during active unmedicated labour). The lethal combination of an expanded metabolic O 2 \text{O}_2 O 2 ​ demand and a severely depleted oxygen reservoir (FRC) causes arterial oxygen saturation to plummet precipitously during hypoventilation or apnea. Rigorous pre-oxygenation with 100% O 2 \text{O}_2 O 2 ​ for 3 minutes of tidal breathing (or 8 vital capacity breaths) with an airtight mask seal is mandatory prior to general anaesthesia induction.

Upper Airway Edema and Difficult Airway Anatomy

Capillary Engorgement: Estrogen induces widespread capillary hyperemia, mucosal engorgement, and friability throughout the nasopharynx, oropharynx, larynx, and false vocal folds.

Anatomical Narrowing: The laryngeal aperture narrows, and the tissues bleed easily upon minor trauma. Forceful suctioning or instrumentation through the nose (such as nasotracheal tubes or nasopharyngeal airways) carries a high risk of severe epistaxis and is contraindicated.

Mallampati Grade Progression: Water retention, intrapartum intravenous fluid administration, and prolonged pushing during active labour often increase the Mallampati score by one or two grades between admission and delivery.

Airway Equipment Selection: Due to glottic and subglottic edema, smaller endotracheal tubes are required. A 6.0 to 6.5 mm internal diameter (ID) cuffed endotracheal tube is the standard first choice for adult parturients undergoing general anaesthesia, with a 5.5 mm tube immediately available on the difficult airway cart.

3. Gastrointestinal Adaptations and Mendelson's Syndrome

Pregnancy substantially impairs the mechanical and biochemical barriers that safeguard against gastroesophageal reflux and aspiration pneumonitis.

Barrier Pressure and Anatomical Shifts

Lower Esophageal Sphincter (LES) Dysfunction: Circulating progesterone relaxes gastrointestinal smooth muscle, significantly decreasing LES resting tone. The normal gastroesophageal barrier pressure—defined as the difference between LES resting pressure and intragastric pressure ( P barrier = P LES − P gastric P_{\text{barrier}} = P_{\text{LES}} - P_{\text{gastric}} P barrier ​ = P LES ​ − P gastric ​ )—is substantially reduced.

Displacement of the Stomach: As the uterus expands into the upper abdomen, it shifts the stomach cephalad and to the left, rotating it horizontally. This distorts the gastroesophageal junction, flattening the physiological acute angle of His and compromising the functional antireflux valve.

Placental Gastrin and Acidity: The syncytiotrophoblast secretes gastrin, stimulating parietal cells and promoting hypersecretion of gastric hydrochloric acid. Consequently, resting gastric volumes are elevated and baseline intragastric pH is lower.

Gastric Emptying Dynamics

Antenatal vs Intrapartum Emptying: In non-labouring parturients, gastric emptying of clear fluids and solids is largely normal. However, during active labour , gastric emptying is severely delayed or ceases entirely due to high endogenous sympathetic tone, anxiety, pain, and the administration of systemic opioids (e.g. parenteral fentanyl, morphine, or pethidine).

Full Stomach Paradigm: From 16 to 20 weeks gestation until 48 hours postpartum , all pregnant patients are classified as having a "full stomach" regardless of reported fasting intervals.

Mendelson's Syndrome and Aspiration Prophylaxis

Definition: Mendelson's syndrome refers to chemical aspiration pneumonitis caused by the inhalation of acidic gastric contents. The classical physiological thresholds for developing severe chemical pneumonitis are:

  • Gastric fluid volume > 25 mL > 25\text{ mL} > 25 mL (or > 0.4 mL/kg > 0.4\text{ mL/kg} > 0.4 mL/kg )
  • Gastric fluid pH < 2.5 \text{pH} < 2.5 pH < 2.5

Aspiration Prevention Protocol: Whenever general anaesthesia is required in an obstetric patient, a standard Rapid Sequence Induction (RSI) with cricoid pressure (Sellick's maneuver: 10 N awake, increasing to 30 N upon loss of consciousness) and immediate tracheal intubation with a cuffed tube is mandatory. Pharmacological prophylaxis includes:

Non-particulate antacid: 30 mL of 0.3 M sodium citrate orally 15-30 minutes prior to induction to rapidly buffer existing gastric acid.

H 2 H_2 H 2 ​ -receptor antagonist: Famotidine (oral or IV; ranitidine has been withdrawn in many countries since 2020) to inhibit further parietal cell acid production.

Prokinetic: Metoclopramide 10 mg IV to increase LES tone and accelerate gastric emptying.

4. Haematological Adaptations and Coagulation Cascade

Pregnancy creates a state of physiological hypercoagulability , representing an evolutionary adaptation to curb severe haemorrhage during placental separation. [ PROTHROMBOTIC BALANCE AT TERM ]

  • |
  • +---------------------------+---------------------------+
  • | |
  • [ Procoagulant Factors Rise ] [ Anticoagulant Deficits ]
  • Fibrinogen (Factor I): +50-100% (4-6 g/L) - Protein S Activity: Marked Fall
  • Factors VII, VIII, IX, X, XII: Increased - Protein C Resistance: Increases
  • von Willebrand Factor (vWF): Markedly Increased - PAI-1 and PAI-2: Elevated (from Placenta)
  • Coagulation Factor Alterations

Fibrinogen (Factor I): Plasma concentrations increase by 50% to 100% , rising from normal non-pregnant levels of 2.0 to 4.0 g/L up to 4.0 to 6.0 g/L at term. In obstetric haemorrhage, a fibrinogen level < 2 g/L < 2\text{ g/L} < 2 g/L is an early, highly sensitive predictor of severe postpartum haemorrhage and requires immediate cryoprecipitate or fibrinogen concentrate transfusion.

Vitamin K-Dependent and Contact Factors: Factors VII, VIII, IX, X, XII, and von Willebrand factor (vWF) rise significantly. Prothrombin (Factor II) and Factor V exhibit mild or negligible increases.

Endogenous Anticoagulants: Total and free Protein S concentrations fall substantially due to increased binding to C4b-binding protein. Acquired resistance to activated protein C (APC) develops in over 40% of parturients by the third trimester. Antithrombin III (AT-III) and Protein C levels remain unchanged or experience a slight decline.

Fibrinolysis: Fibrinolytic activity is suppressed throughout pregnancy, primarily due to placental synthesis of plasminogen activator inhibitor-1 (PAI-1) and plasminogen activator inhibitor-2 (PAI-2) . Fibrinolytic suppression rapidly reverses within hours of placental delivery.

Platelet Dynamics: Platelet counts decrease slightly as gestation progresses. In 5% to 8% of healthy pregnancies, asymptomatic gestational thrombocytopenia occurs ( 100 × 10 9 / L 100 \times 10^9/\text{L} 100 × 1 0 9 / L to 149 × 10 9 / L 149 \times 10^9/\text{L} 149 × 1 0 9 / L ), resulting from hemodilution and accelerated platelet turnover in the uteroplacental circuit. Platelet function remains normal.

Venous Thromboembolism (VTE) Risk: The hypercoagulable milieu, along with venous stasis in the lower extremities from pelvic venous compression, produces a 5- to 10-fold higher risk of deep vein thrombosis and pulmonary embolism during pregnancy, and up to a 20- to 30-fold higher risk in the immediate 6-week postpartum period.

  • 5. Uteroplacental Circulation and Hemodynamics
  • Perfusion Dynamics and Absence of Autoregulation

Volumetric Blood Flow: Uterine blood flow increases dramatically from ~50 mL/min in the non-pregnant uterus to 700 to 900 mL/min at term , representing approximately 10% to 12% of maternal cardiac output . Roughly 85% to 90% of this flow directly traverses the intervillous space to bathe the fetal trophoblast.

Spiral Artery Remodeling: Extravillous cytotrophoblasts invade the maternal spiral arteries, replacing their muscular media and internal elastic lamina with an amorphous, dilated, fibrinoid matrix. This converts high-resistance, responsive maternal arterioles into wide, flaccid, low-resistance conduits.

No Autoregulatory Capacity: Because the spiral arteries lose their smooth muscle architecture, the uteroplacental vascular bed is maximally dilated under basal conditions and lacks autoregulation . Uteroplacental blood flow is passive and depends entirely on the perfusion pressure gradient.

The Uterine Perfusion Pressure Equation

Uteroplacental blood flow ( U B F UBF U BF ) is dictated by the physiological perfusion equation:

U B F ∝ U P P = U A P − U V P U V R UBF \propto UPP = \frac{UAP - UVP}{UVR} U BF ∝ U PP = U V R U A P − U V P ​

where:

  • U P P UPP U PP = Uterine Perfusion Pressure
  • U A P UAP U A P = Uterine Arterial Pressure (equivalent to maternal mean systemic arterial pressure, MAP)
  • U V P UVP U V P = Uterine Venous Pressure
  • U V R UVR U V R = Uterine Vascular Resistance
  • Clinical Determinants Impairing Uteroplacental Flow

Decreased Uterine Arterial Pressure ( U A P UAP U A P ):

Maternal arterial hypotension resulting from spinal or epidural sympathectomy.

Aortocaval compression in the supine position.

Hypovolaemia from peripartum haemorrhage.

Overly deep general anaesthetic depth.

Increased Uterine Venous Pressure ( U V P UVP U V P ):

Inferior vena caval compression.

Uterine contractions (intrauterine pressure rises from a resting 8-12 mmHg up to 50-70 mmHg at the peak of contraction, momentarily arresting intervillous blood flow).

Uterine hypertonus / tachysystole (often caused by oxytocin or carbetocin overdose).

Maternal pushing and Valsalva maneuvers.

Increased Uterine Vascular Resistance ( U V R UVR U V R ):

Endogenous catecholamine surges induced by maternal pain, distress, or severe hypoxemia/hypercapnia.

Preeclampsia with severe endotheliopathy and vasospasm.

Pharmacological administration of potent, non-titrated alpha-1 adrenergic receptor agonists (e.g. high-dose phenylephrine, noradrenaline, adrenaline).

Clinical Pearl on Vasopressors: Phenylephrine is the first-line vasopressor for post-spinal hypotension in obstetrics because it maintains normal fetal acid-base balance better than ephedrine (ephedrine crosses the placenta and stimulates fetal beta-receptors, increasing fetal metabolism and causing mild fetal acidosis). However, phenylephrine must be titrated carefully to restore maternal MAP without causing excessive systemic vasoconstriction or reflex bradycardia, which can compromise uteroplacental perfusion.

  • 6. Placental Drug Transfer and Perinatal Pharmacology
  • Fick's Law of Placental Diffusion

The transfer of anaesthetic agents and adjuvant medications across the syncytiotrophoblast membrane occurs predominantly via simple, passive transcellular diffusion, governed by Fick's first law of diffusion :

Rate of Diffusion = K ⋅ A ⋅ ( C m − C f ) D \text{Rate of Diffusion} = \frac{K \cdot A \cdot (C_m - C_f)}{D} Rate of Diffusion = D K ⋅ A ⋅ ( C m ​ − C f ​ ) ​

where:

  • K K K = Diffusion coefficient of the drug (determined by lipid solubility and molecular size)
  • A A A = Surface area available for exchange (~12-14 m 2 \text{m}^2 m 2 at term)

C m − C f C_m - C_f C m ​ − C f ​ = Transplacental concentration gradient between maternal and fetal free, unbound drug

D D D = Diffusion distance / membrane thickness (decreases from ~25 μ m \mu\text{m} μ m in early pregnancy to ~2-4 μ m \mu\text{m} μ m at term) [ FICK'S DIFFUSION DETERMINANTS ]

  • |
  • +-------------------------------+-------------------------------+
  • | | |
  • [ High Placental Transfer ] [ Moderate Transfer ] [ Clinically Negligible Transfer ]
  • Low Molecular Weight (<500 Da) - MW 500-1000 Da - High Molecular Weight (>1000 Da)
  • Highly Lipophilic - Moderately Ionized - Completely Ionized / Quaternary Ammonium
  • Low Ionization (Non-polar) - Highly Polar / Water-soluble
  • Low Maternal Protein Binding - High Maternal Protein Binding
  • Physicochemical Determinants Favoring Rapid Transfer

Molecular Weight:

< 500 Da < 500\text{ Da} < 500 Da : Crosses readily by passive diffusion (virtually all anaesthetic induction agents, volatile gases, opioids, and local anaesthetics).

500 to 1000 Da 500 \text{ to } 1000\text{ Da} 500 to 1000 Da : Crosses at an intermediate, slower rate.

> 1000 Da > 1000\text{ Da} > 1000 Da : Impenetrable to passive diffusion (e.g. heparin, protamine).

Lipid Solubility: Highly lipophilic, uncharged molecules dissolve rapidly into the lipid bilayer of the placental trophoblast and diffuse swiftly down their concentration gradients.

Degree of Ionization: Only the unionized drug fraction is lipid-soluble and capable of diffusing across membranes. Highly ionized compounds cannot penetrate the lipid core of the syncytiotrophoblast.

Protein Binding: Only the free, unbound fraction of drug in maternal plasma is available to diffuse across the placental barrier. Acidic drugs bind predominantly to albumin; basic drugs bind to alpha-1 acid glycoprotein ( α 1 \alpha_1 α 1 ​ -AGP).

Pharmacological Class Representative Drugs Placental Permeability Clinical & Pharmacological Mechanism

Inhalational Agents Sevoflurane, Isoflurane, Desflurane High Low MW ( < 200 Da <200\text{ Da} < 200 Da ), uncharged, highly lipophilic. Rapid equilibrium; prolonged maternal exposure causes fetal CNS depression.

Intravenous Inductions Propofol, Thiopental, Ketamine, Etomidate High Low MW, highly lipophilic. Crosses within 1 minute; fetal effects minimized by rapid tissue redistribution and maternal clearance.

Opioids Fentanyl, Morphine, Remifentanil High Lipophilic, crosses rapidly. Remifentanil is uniquely safe due to rapid hydrolysis by fetal non-specific tissue and blood esterases.

Benzodiazepines Midazolam, Diazepam High Small, lipophilic. Crosses rapidly; high doses induce "floppy infant syndrome" (hypotonia, hypothermia, respiratory depression).

Neuromuscular Blockers Suxamethonium, Rocuronium, Vecuronium, Atracurium Clinically Negligible Quaternary ammonium compounds , permanently ionized with positive charges, highly water-soluble. Do not cross placenta in therapeutic doses; completely safe for the fetus.

Anticholinergics Atropine vs Glycopyrrolate Atropine: High ; Glycopyrrolate: None Atropine is a tertiary amine (unionized, lipophilic → \rightarrow → crosses, causes fetal tachycardia). Glycopyrrolate is a quaternary ammonium (ionized → \rightarrow → cannot cross).

Anticoagulants Warfarin vs Heparin / LMWH Warfarin: High ; Heparin: None Warfarin has low MW ( 308 Da 308\text{ Da} 308 Da ) and crosses (teratogenic embryopathy, fetal intracranial bleeding). Unfractionated heparin and LMWH are large polar mucopolysaccharides ( > 5000 Da >5000\text{ Da} > 5000 Da ) and do not cross.

Local Anaesthetics Bupivacaine, Lidocaine, Ropivacaine High Weak bases. Crosses as unionized fraction. Can cause fetal ion trapping during fetal distress.

Fetal Ion Trapping Mechanism

Local anaesthetics are weak bases with dissociation constants ( p K a pK_a p K a ​ ) ranging between 7.7 and 8.1. In maternal blood (normal pH 7.40), a substantial portion of the drug exists in the unionized, lipophilic form ( B B B ), which readily crosses the placental syncytiotrophoblast.

In the healthy fetus, normal umbilical arterial pH is approximately 7.32 to 7.35. However, in the setting of fetal distress, prolonged hypoxaemia, or placental insufficiency , the fetus develops metabolic and lactic acidosis (fetal pH dropping to < 7.15 < 7.15 < 7.15 ). When the unionized local anaesthetic molecule ( B B B ) enters the acidic fetal circulation, the excess hydrogen ions ( H + H^+ H + ) drive the equilibrium toward the protonated, ionized conjugate acid ( B H + BH^+ B H + ):

B + H + ⇌ B H + B + H^+ \rightleftharpoons BH^+ B + H + ⇌ B H +

Because the ionized molecule ( B H + BH^+ B H + ) carries a positive charge, it is lipophobic and completely impermeable to the lipid placental membrane . The ionized drug is effectively "trapped" in the fetal blood, unable to diffuse back down its concentration gradient into maternal circulation. This leads to toxic accumulation of local anaesthetic in the fetal tissues, causing refractory fetal bradycardia, myocardial depression, and profound neonatal neurotoxicity upon delivery.